Biomarker Data Management in Clinical Trials: Addressing the Challenges of the New Regulatory Landscape
|
|
- Darrell Parsons
- 6 years ago
- Views:
Transcription
1 Biomarker Data Management in Clinical Trials: Addressing the Challenges of the New Regulatory Landscape
2 Introduction Biomarkers and specialty labs are core to modern clinical trials.the broad and evergrowing set of assays can range from targeted panels to high-content or high-throughput experiments. Biological techniques are seemingly boundless and continuously evolving, especially in complex areas such as oncology, immunology, and genetics, with data being generated from flow cytometry, next generation sequencing, immunosequencing, mutational analysis, gene or protein expression, immunohistochemistry, circulating tumor cells, cytogenetics, and others. Evaluating biomarkers in clinical trials and integrating specialty lab data with PK, safety labs, and clinical data provide a more complete picture for assessing drug efficacy and safety. The process presents a unique challenge for drug developers, however, as they simultaneously endeavor to conduct innovative clinical research while complying with regulatory requirements for submission. Prior to 2017, there was some flexibility in how data could be submitted to FDA; this changed in December 2016 when FDA s binding guidance document on study data exchange standards, issued in December 2014, went into full effect. Any study beginning after December 17, 2016 must use the appropriate FDA-supported standards, formats, and terminologies specified in the FDA Data Standards Catalog (see section II.C) for NDA, ANDA, and certain BLA submissions. The current catalog specifies use of the CDISC SDTM, SEND, ADaM and Define-XML standards, as well as CDISC Controlled Terminology. When it comes to specialty lab data, the data exchange standards in many cases are still developing, and SDTM programming typically requires expert input to determine how complex lab data can be mapped appropriately. Even when implementation guides exist, mapping requires an in-depth understanding of the complexity, quality control, and processing that are appropriate for each assay in order to transform raw data files into CDISC-compliant data sets.
3 A Case Study in Preparing Specialty Lab Data for FDA Submission The key challenges and steps involved in transforming specialty lab data into CDISC-compliant data sets that conform to FDA data exchange standards can be illustrated in the context of a phase 1/2 dose escalation and expansion study of an immuno-oncology (IO) compound. Phase 1/2 Study Objectives On-study Pull together in real-time, visualize and report on specialty lab data in context of other labs and clinical data to aid in clinical decision making End of Study Generate and deliver CDISC-compliant data sets for specialty lab data to be used in analysis and submission, with both rigor and fast turnaround 4 specialty lab assays coming from 3 specialty labs, and other protocol required lab tests coming from local labs at clinical sites LAB 1 LAB 2 LAB 3 PK lab work and multiplex cytokine panel Gene expression by Nanostring Immunophenotyping by flow cytometry Clinical sites and local labs Safety lab data hematology, chemistry PK lab data Specialty biomarker assays - High-content flow cytometry - Multiplex cytokine panel - Gene expression measured by Nanostring 3
4 Managing Lab Data: Use of Technology and the SDTM Workflow For context on the challenges of processing specialty lab data and transforming these data into CDISC-compliant data sets, the typical workflows for local labs and PK data are illustrated (Figure 1) with consideration to differences in data processing (eg, technology driven vs manual) and SDTM mapping (eg, single, well-defined domain vs multiple, more complex domains). Of particular importance is the use of EDC technology and lab management tools in the more established workflow for local labs. By extension, technology engineered for specialty lab data could have a similar impact on industry s ability to deliver specialty lab data under the same regulations in an efficient, high quality manner. Figure 1. Source Data Processing SDTM Workflow SDTM Domains Local labs at clinical sites - Hematology - Chemistry Within EDC system - Technology-enabled data processing in EDC (queries, edit checks, remote review) - Lab management tools to manage reference ranges Single domain - Generally most complex domain for data coming from EDC, but significantly less complex than specialty labs - SDTM programming is part of typical DM and programming workflow Laboratory Test Results (LB) Specialty PK group - Drug concentrations over time - Modeling generates other PK parameters (e.g., C max, t max, AUC) External to EDC system - Typically manual processing by PK group - Basic reconciliation with EDC, but remainder is handled separate from CDM workflow Multiple domains - Generally more complex than local labs and requires coordination with PK group - SDTM programming for PK may be handled by PK vendor further coordination Pharmaco-kinetic Concentrations (PC) Pharmaco-kinetic Parameters (PP) Related Records (RELREC) Specialty biomarker labs - Multiplex cytokine panel - High-content flow cytometry - Nanostring gene expression External to EDC system - Typically manual processing, often by translational team - Highly specialized QC and processing pipelines - Handled separate from CDM workflow and often not fully processed until post-study Multiple specialty domains - CDISC implementation and controlled terminology is partially defined (e.g., SDTM IG-PGx) - Historically, these biomarker data have been treated as exploratory and not included in the data submission to FDA Laboratory Test Results (LB) Custom Domains Biospecimen Events (BE) Pharmaco-genomic Findings (PF) Pharmaco-genomic Biomarker (PB) Biospecimen Findings (BS) PGx Methods and Supporting Information (PG) Subject Biomarker (SB) Related Specimens (RELSPEC) 4
5 Challenges of Handling Specialty Biomarker Data in SDTM Workflow 1. Complexity in biomarker assays. To enable mapping of raw data into SDTM, extensive processing is typically needed that requires in-depth understanding of the biological assay. For example, NanoString technology outputs Reporter Code Count (RCC) files that require sample level checks (RNA integrity, field-of-view ratios, and binding densities), background correction, and normalization to obtain usable gene expression values. 2. Lack of structure in biomarker data upstream of SDTM mapping. Generally, the source biomarker data will be delivered in disparate file formats with inconsistent structure across assays and data sets. This is further compounded by the lack of standards across labs. All of this combined makes it difficult to standardize downstream programming pipelines. 3. Meeting submission timelines. Delivery of submission-ready data sets for downstream use is a time-sensitive component of activities post database lock. Simply adding the handling of complex, often messy biomarker data within the traditionally rigid, process-driven SDTM workflow without consideration to new ways of dealing with these data is a recipe for failure. Historically, specialty lab data has been out-of-scope of the rapid turnaround delivery schedule post-database lock, but this is no longer the case. Applying New Technologies to Managing Specialty Lab Data and SDTM Mapping Biomarker data being submitted to the FDA will be subject to FDA data exchange standards for regulatory submission, making it critical to organize these data effectively and efficiently as part of the end-of-study activities. Additionally, biomarker data are often used to support on-study decisions. Given this dual role, development of a robust end-to-end solution for managing biomarker data needs to consider regulated objectives, such as SDTM programming for analysis and submission, as well as provide flexibility to meet on-study needs, such as data visualization and reporting for safety review, data monitoring, and decisions on maximum tolerated dose. Similar to how EDC technology helped revolutionize clinical data management, a technology-based solution for biomarker data management is now required to meet the needs of modern clinical trial operations. However, technology alone is not enough to achieve success in biomarker data management; it also depends on biomarker subject matter experts and associated biomarker data management processes that provide a rigorous, agile biomarker data management system for clinical trials. 5
6 This new model harmonizes disparate sources of biomarker data and stores them in a centralized database for more effective on-study and downstream use. From that point, experts with knowledge of specialty labs and CDISC standards can map biomarker data to the correct SDTM domain. This approach, as illustrated in the chart below, produces downstream efficiencies through more effective variable mapping and development of reusable macros and codes. Beyond enabling timely delivery post-database lock, it also provides for maximal use of biomarker data to inform decisions throughout the study by providing clinical trial professionals and sponsors with centralized, on-demand access to biomarker data. Figure 2. Electronic Data Capture & Clinical Data Management Multiple clinical sites participating in clinical trial Ongoing data entry by study coordinators via EDC system user interface Data processing with edit checks, queries, manual review and clinical programming Store clinical data in centralized clinical Db and extract data in EDC supported format(s) Transform data to CDISC-compliant data sets using SDTM programming pipeline approach and efficiencies vary by organization Generate applicable SDTM domains containing clinical data for use in analysis and submission Clinical Data Management Technology for Specialty Lab Data & Biomarker Data Management.RCC.CSV.FCS One or more specialty labs generating data Ongoing bulk upload of raw specialty lab data via web-based application for managing biomarker data Biomarker Data Management Data processing with assay-specific QC, bioinformatics workflows, and lab management Applications for biomarker data visualization and reporting can aid in on-study decision making Store biomarker data in centralized relational Db and extract data in structured multi-purpose format Transform data to CDISC-compliant data sets using biomarker SME and SDTM programming pipeline (standards, macros) Generate applicable SDTM domains containing biomarker data for use in analysis and submission With biomarkers being an integral part of modern clinical trials, it is necessary to bring new approaches to the management and processing of biomarker data. Combining advanced technology with biomarker expertise provides flexibility, efficiency, and compliance. Addressing the fundamental gap in clinical trial operations and translational research with this approach, in parallel to traditional clinical data management, will result in immediate gains and mitigate risks to interim and final study deliverables. 6
7 7
8 2 Bethesda Metro Center, Suite 850 Bethesda, MD office precisionformedicine.com
Introducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration
Introducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration 1 2 Translational Informatics Overview Precision s suite of services is
More informationSpecialty Lab Services. Deep science at scale
Specialty Lab Services Deep science at scale Advancing biomarker research Our broad expertise and global laboratory footprint deliver deep science at scale Specialty assays drive insight into preclinical
More informationSDTM and SEND An Integrated View and Approach
SDTM and SEND An Integrated View and Approach PhUSE Connect 2018 Veena Nataraj Cheryl Riel Overview Nonclinical and Clinical Development Phase Regulatory Agency Needs Deliverables to Regulatory Agencies
More informationDRIVING CLINICAL DATA STANDARDS BEYOND COMPLIANCE
SMARTER DRUG DEVELOPMENT DRIVING CLINICAL DATA STANDARDS BEYOND COMPLIANCE Binding FDA requirements take effect in 2016 will your data standards platform do more than simply comply? INTRODUCTION In December
More informationPreclinical Data Standardization Process for regulatory submission to U.S. Food and Drug Administration
Preclinical Data Standardization Process for regulatory submission to U.S. Food and Drug Administration Gabriele Pesavento, 23 May 2018 Aptuit An Evotec company A full service CRO that delivers purpose
More informationSEND Introduction CDISC User Group Meeting. Gitte Frausing. Principal Consultant Data Standards Decisions. Insight Interpretation Implementation
French CDISC User Group Meeting May 2018 1 Insight Interpretation Implementation SEND Introduction 2018 CDISC User Group Meeting Gitte Frausing Principal Consultant Data Standards Decisions French CDISC
More informationCDISC Standards: Current and Future
CDISC 2010 CDISC Standards: Current and Future CDISC Japan Interchange Tokyo, Japan 20 July 2010 Rebecca D. Kush, PhD President and CEO, CDISC Clinical Research Standards (Content) (Protocol-driven Research;
More informationSAS Life Science Analytics Framework
CDISC Italian User Network Day 21Oct2016 (Data standard e loro applicazione) SAS Life Science Analytics Framework STIJN ROGIERS - SAS SENIOR INDUSTRY CONSULTANT GLOBAL PRACTICE, HEALTH & LIFE SCIENCES
More informationEnd-to-End Management of Clinical Trials Data
End-to-End Management of Clinical Trials Data A Revolutionary Step Toward Supporting Clinical Trials Analysis Over the Next Decades of Clinical Research WHITE PAPER SAS White Paper Table of Contents Introduction....
More informationStandardize Study Data for Electronic Submission
PharmaSUG China 2018 - Paper CD-43 ABSTRACT Standardize Study Data for Electronic Submission Qin Li, Regeneron Pharmaceuticals Inc. In December 2014, FDA announced that submissions under NDAs, ANDAs, BLAs,
More informationSymphony Genomics Workflow Management System Managing, Integrating, and Delivering Your NGS Data and Results
Symphony Genomics Workflow Management System Managing, Integrating, and Delivering Your NGS Data and Results Precision Genomics for Immuno-Oncology www.personalis.com info@personalis.com 1 855-GENOME4
More informationOctober, Integration and Implementation of CDISC Standards
Integration and Implementation of CDISC Standards October, 2008 Barbara Lentz, Associate Director, Electronic Data Management Standards, Processes & Training Pat Majcher, Statistical Reporting Services
More informationPutting CDISC Standards to Work How Converting to CDISC Standards Early in the Clinical Trial Process Will Make Your CDISC Investment Pay
How Converting to CDISC Standards Early in the Clinical Trial Process Will Make Your CDISC Investment Pay Jon Roth, Vice President, Data Sciences & Biometrics Authorized Trainer for ADaM, CDISC Mark Vieder,
More informationFrom Standards that Cost to Standards that Save: Cost Effective Standards Implementation
From Standards that Cost to Standards that Save: Cost Effective Standards Implementation Jeffrey M. Abolafia, Rho, Chapel Hill, NC Frank DiIorio, CodeCrafters Inc., Philadelphia, PA Warning This presentation
More informationSimplifying Clinical Trials
Simplifying Clinical Trials A division of Phoenix Progressive Certifications Enterprise Pvt. Ltd. A division of Phoenix Progressive Certifications Enterprise Pvt. Ltd. Company Overview : PPCE is an efficient
More informationHarnessing the power of clinical data
Harnessing the power of clinical data Harnessing the power of clinical data Managing the data burden Life sciences companies are rich in data and gaining exponentially more clinical data all the time.
More informationSupporting A Data Review and Visualization Application With SDTM
Paper DV09 Supporting A Data Review and Visualization Application With SDTM Deepika Sunkara, MS, Covance, King of Prussia, Pennsylvania Jagadish Dhanraj, MS, Medimmune, Gaithersburg, Maryland ABSTRACT
More informationBIOMETRICS SERVICES ADVISORY DATA OFFICE UNBLINDING SECURE INDEPENDENT TEAM PROGRAM. ADaM TRAINER SAFETY SDTM COMPLIANT TA-EXPERTISE SDTM DATA
BIOMETRICS SERVICES DELIVER UNBLINDED DATASETS TO IDMC SDTM-IG UNBLINDING ADVISORY QUALITY ON TIME DEDICATED DATA SECURE BOARD EMERGENCY PARTNERSHIPTEAM DATA OFFICE UNBLINDING INVESTINGEXPERTISE SHARING
More informationDeployment of SAS Programming Contract Staff: Pathway to Sinkhole or Best Strategy for Programming Division? Parag Shiralkar, Eliassen Group, NJ, USA
PharmaSUG 2013 Paper MS04 Deployment of SAS Programming Contract Staff: Pathway to Sinkhole or Best Strategy for Programming Division? Parag Shiralkar, Eliassen Group, NJ, USA Abstract In pharmaceutical
More informationBIOCLINICA CLINICAL DATA MANAGEMENT
BIOCLINICA CLINICAL DATA MANAGEMENT Achieve faster speed to market, with Bioclinica s best-in-class Electronic Data Capture (EDC) technology and in-house full-service Data Management (DM) services. $ BIOCLINICA
More informationBest Practices for Managing Clinical Research Information
Best Practices for Managing Clinical Research Information David Handelsman Principal Strategist, Clinical Research & Development SAS Copyright 2005, SAS Institute Inc. All rights reserved. 2 This talk
More informationCDISC Journal. Genzyme s GetSMART Program: Implementing Standards End-to-End
CDISC Journal Clinical Data Interchange Standards Consortium O ctober 2011 Genzyme s GetSMART Program: Implementing Standards End-to-End By Sue Dubman, Brooke Hinkson, Dana Soloff, David Fritsche and PK
More informationImplementing Clinical Trial Data Standards
Bernd Doetzkies, Director Informatics Daiichi Sankyo Pharma Development PRISME Forum SIG Meeting 17Oct2011 Implementing Clinical Trial Data Standards Clinical Development Business Trends Resistance to
More informationCLINICAL DATA MANAGEMENT
CLINICAL DATA MANAGEMENT Clinical Data Management is involved in all aspects of processing the clinical data, working with a range of computer applications, database systems to support collection, cleaning
More informationSAS Drug Development in action: efficient standards libraries and study management modules together called CDmation.
SAS Drug Development in action: efficient standards libraries and study management modules together called CDmation. Mark Lambrecht (SAS) Peter Van Reusel (Business & Decision Life Sciences) The clinical
More informationClinical Data in Business Intelligence
Paper DV07 Clinical Data in Business Intelligence Mike Collinson, Oracle Heath Sciences Consulting (HSC), Reading, UK ABSTRACT Clinical organizations are under increasing pressure to execute clinical trials
More informationCDISC Controlled Terminology: Let s Speak the Same Language
CDISC Controlled Terminology: Let s Speak the Same Language DCDISC User Network November 8, 2011 Chris Tolk Director, Terminology Agenda Overview / Objectives Key Drivers Terminology Development SDTMIG
More information9th Annual SAS Health Care & Life Sciences Executive Conference
: An Integrated Platform to Promote Data Exchange, Collaboration, and Advanced Analytics 9th Annual SAS Health Care & Life Sciences Executive Conference 9-10 May 2012 Bernd Doetzkies, Director Informatics
More informationIndustrialized Clinical Data Standards Management Speed of automation, Power of accuracy and Transforming clinical data into business intelligence
Industrialized Clinical Standards Management Speed of automation, Power of accuracy and Transforming clinical data into business intelligence Executive Summary The majority of commercially available legacy
More informationMANAGING AND INTEGRATING CLINICAL TRIAL DATA: A Challenge for Pharma and their CRO Partners
MANAGING AND INTEGRATING CLINICAL TRIAL DATA: A Challenge for Pharma and their CRO Partners Within the Pharmaceutical Industry, nothing is more fundamental to business success than bringing drugs and medical
More informationMegan Schmidt Vice President of Product Management, CompuGroup Medical
Thursday April 6, 2017 A01 Molecular and Genetic Testing: How to Position your Laboratory for New Technology Megan Schmidt Vice President of Product Management, CompuGroup Medical DESCRIPTION: Molecular
More informationInnovative Clinical Development Solutions
Innovative Clinical Development Solutions epro Data Integration with Rave : Case Studies With and Without Patient Cloud November 10, 2017 Kathy Zheng Background PROMETRIKA was the first Medidata CRO partner
More informationSteps and Slides of Implementing Global Standards Producing High Quality Programming Outputs Edition
Steps and Slides of Implementing Global Standards Producing High Quality Programming Outputs Edition David Izard, MS Terek Peterson, MBA Richard Addy, MS CDISC ODM SDTM LAB CDASH ADaM PRM SEND Controlled
More informationINTRODUCING CLINIC AUTOMATION IN A PHASE I UNIT WITH END-TO-END E-SOURCE DATA PROCESSING
INTRODUCING CLINIC AUTOMATION IN A PHASE I UNIT WITH END-TO-END E-SOURCE DATA PROCESSING Wim Verreth 4 th Annual Outsourcing in Clinical Trials 21-22 May 2014 OUTLINE What is Clinical Automation? Why we
More informationWelcome to the American College of Toxicology s Webinar Series. We will begin at 11AM EDT
Welcome to the American College of Toxicology s Webinar Series We will begin at 11AM EDT Preparing for Nonclinical edata Regulatory Submissions to the US FDA SEND and Beyond September 5, 2013, 11:00 AM
More information227 AP and >100 CDx engagements
Anatomic pathology Q 2 Solutions comprehensive in-house end-to-end anatomic pathology and adjunct molecular services are designed to meet your clinical trial needs. Anatomic pathology is a vital part of
More informationMANAGING AND ANALYZING CLINICAL DATA MARK LAMBRECHT, PRINCIPAL INDUSTRY CONSULTANT, SAS BIAS MEETING, MARCH 14 TH 2014, MILAN, ITALY.
MANAGING AND ANALYZING CLINICAL DATA MARK LAMBRECHT, PRINCIPAL INDUSTRY CONSULTANT, SAS BIAS MEETING, MARCH 14 TH 2014, MILAN, ITALY. TABLE OF CONTENTS SAS and CDISC Clinical trial challenges The promise
More informationNEW AGILE CLINICAL TRIALS SUCH AS ADAPTIVE DESIGNS AND THE USE OF THE SAS LIFE SCIENCE ANALYTICAL FRAMEWORK
NEW AGILE CLINICAL TRIALS SUCH AS ADAPTIVE DESIGNS AND THE USE OF THE SAS LIFE SCIENCE ANALYTICAL FRAMEWORK DR. MARK LAMBRECHT, ADVISORY INDUSTRY CONSULTANT SAS HEALTH AND LIFE SCIENCES GLOBAL PRACTICE
More informationPhUSE Paper PP07. EPOCH in Reverse. Ann Croft, LEO Pharma, Hurley, UK
Paper PP07 EPOCH in Reverse Ann Croft, LEO Pharma, Hurley, UK ABSTRACT After supplying test data through the electronic gateway to the FDA, LEO Pharma was informed that the FDA required some updates to
More informationAchieves International Standards
Rising to Excellence How a China CRO Achieves International Standards Helen Yin, VP & GM Tigermed-MacroStat Minzhi Liu, GM, MacroStat July 7 th, 2012 1 Outline Selecting excellent staff Training staff
More informationHELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY
HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT PPD IS A PARTNER WITH PROVEN CAPABILITIES THAT SUPPORT AND ADVANCE ONCOLOGY RESEARCH
More informationThe Evolution of SDTM
The Evolution of SDTM What s new? Tina Apers CRO Manager Mobile +32 476 60 08 79 tina.apers@businessdecision.com Business & Decision Life Sciences Tel +32 2 774 11 00 Fax +32 2 774 11 99 Sint-Lambertusstraat
More informationCDISC Controlled Terminology: Let s Speak the Same Language. CDISC User Group Meeting March 12, 2009
CDISC Controlled Terminology: Let s Speak the Same Language CDISC User Group Meeting March 12, 2009 Agenda Key Terminology Objectives Key Drivers Terminology Production and Development Future Plans 2 Terminology
More informationDNA. Clinical Trials. Research RNA. Custom. Reports CLIA CAP GCP. Tumor Genomic Profiling Services for Clinical Trials
Tumor Genomic Profiling Services for Clinical Trials Custom Reports DNA RNA Focused Gene Sets Clinical Trials Accuracy and Content Enhanced NGS Sequencing Extended Panel, Exomes, Transcriptomes Research
More informationConformance Rules how to follow and comply when specified by multiple sources?
Conformance Rules 05-Nov-2018 1 Conformance Rules how to follow and comply when specified by multiple sources? PhUSE EU Connect 2018 Francis Dsa Agenda Conformance Rules 05-Nov-2018 2 Different sources
More informationCAPTURE-BASED APPROACH FOR COMPREHENSIVE DETECTION OF IMPORTANT ALTERATIONS
CAPTURE-BASE APPROACH FOR COMPREHENSIVE ETECTION OF IMPORTANT ALTERATIONS SEQUENCE MUTATIONS MICROSATELLITE INSTABILITY AMPLIFICATIONS GENOMIC REARRANGEMENTS For Research Use Only. Not for iagnostic Purposes.
More informationSpecifications for Electronic Data from Toxicology Studies for Translation to SEND
Specifications for Electronic Data from Toxicology Studies for Translation to SEND SEND Express - Timely and accurate preparation of FDA-Submission ready, validated SEND datasets February 2016 PDS AMERICAS
More informationSAS End-to-End solutions in Clinical Trial Emma Liu, SAS R&D, Beijing, China
PharmaSUG China 2015 - Paper 29 SAS End-to-End solutions in Clinical Trial Emma Liu, SAS R&D, Beijing, China ABSTRACT Are you in trouble with executing timely queries against historical or ongoing clinical
More informationHigh Quality or Poor Quality DB
The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers,
More informationVisualising CDISC SDTM for Monitoring and Review. Philip C. M. Bartle Clinical Innovation, PPD
Visualising CDISC SDTM for Monitoring and Review Philip C. M. Bartle Clinical Innovation, PPD Visualising CDISC SDTM for Monitoring and Review 1 2 3 4 5 6 7 Bringing CDISC SDTM Alive with Spotfire and
More informationCDISC Controlled Terminology across the Clinical Trial Continuum. Bay Area Implementation Network 6 March 2008
CDISC Controlled Terminology across the Clinical Trial Continuum Bay Area Implementation Network 6 March 2008 Bron Kisler Co-Founder / Director of Terminology CDISC Terminology Initiative Overview / Background
More informationEnsuring Data Quality in Animal Health Sponsor Perspective
Ensuring Data Quality in Animal Health Sponsor Perspective Annette Kenser, Quality Assurance Expert, Bayer U.S. LLC Heather Raszka, Principal Specialist, RDQA, Boehringer Ingelheim Animal Health Damon
More informationFDASmart Inc. EDC & CDM Solutions
FDASmart Inc. EDC & CDM Solutions Our Services Validation of EDC Products as per Client Requirement with compliance with FDA s CFR 21 Part 11 Training on EDC Rave Helps to prepare SOPs and SWIs related
More informationCDISC Standards: Summary
Business Case for CDISC Standards: Summary PhRMA-Gartner-CDISC Project September 2006 Carol Rozwell, Gartner Rebecca Daniels Kush, CDISC Ed Helton, SAS Frank Newby, CDISC Tanyss Mason, CDISC Clinical Data
More informationIntegrating Trial Data Processes Across Functional Areas using Electronic Data Capture (EDC) Technology
Integrating Trial Data Processes Across Functional Areas using Electronic Data Capture (EDC) Technology Authors: Bill Gluck, PhD DATATRAK, VP of Clinical and Consulting Services Lorraine D. Ellis, MS,
More informationA Streamlined Data Capture and Exchange Partnership that Delivers Faster Decisions
A Streamlined Data Capture and Exchange Partnership that Delivers Faster Decisions 2011 SAS Health & Life Sciences Conference Michelle Combs, PhD, VP, Clinical Pharmacology Sciences, Celerion Bernd Doetzkies,
More informationCDISC/TransCelerate Collaboration and TransCelerate work streams. -Clinical Data Standards -Common Protocol Template -esource
CDISC/TransCelerate Collaboration and TransCelerate work streams -Clinical Data Standards -Common Protocol Template -esource July 2016 TransCelerate Clinical Data Standards Project Opportunity
More informationSAS & Clinical Data Repository Karthikeyan Chidambaram
SAS & Clinical Data Repository Karthikeyan Chidambaram Cognizant Technology Solutions, Newbury Park, CA Clinical Data Repository (CDR) Drug development lifecycle consumes a lot of time, money and effort.
More informationEvolving Role of the Data Manager
07 November 2016 Evolving Role of the Data Manager 2 Evolution of the Data Manager Role... 2014 2010 Mobility Early 90 s We all simply did it OUR way! No formal measure of data managers' knowledge and
More informationADB Consulting & CRO Inc.
DATA MANAGEMENT, BIO-STATISTICS, CLINICAL OPERATIONS, QUALITY SYSTEMS & STAFFING SERVICES Abbreviated Edition December 2005 Advancing Data Management, Bio-statistics, Clinical Operations, & Quality Systems
More informationCDISC Journal. Current status and future scope of CDISC standards. By Rebecca D. Kush, President and CEO, CDISC. 1. Introduction
CDISC Journal Clinical Data Interchange Standards Consortium oc tober 2012 Current status and future scope of CDISC standards By Rebecca D. Kush, President and CEO, CDISC 1. Introduction In translational
More informationPharmaSUG Paper IB15
PharmaSUG 2016 - Paper IB15 Importance of Niche Provider for Successful NDA Submission: Rescue Case Study Aparna Poona, Vita Data Sciences, Waltham, MA Bhavin Busa, Vita Data Sciences, Waltham, MA Tim
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationClinical Data Management Services
Clinsoft Overview Clinical Trial Management Clinical Data Management Services Medical Writing & Pharmacovigilance Services 2 Overview Started in 2008 with a small group of 7 team members. Expanded to a
More informationCDISC Italian UN Aggiornamento/Attività
CDISC Italian UN Aggiornamento/Attività CDISC Italian User Network Day 27 Ottobre 2017 Angelo Tinazzi (Cytel) - Silvia Faini (CROS NT) E3C members 2 Agenda Risposte Questionario Partecipanti CDISC in a
More informationambiguous insights through HCL s R&D Transformation limit your business
ambiguous insights through HCL s R&D Transformation limit your business Life Sciences industry is undergoing a transformational change - blockbuster patent expirations, global interconnected world, and
More informationSOLUTION BRIEF DOSSIER MANAGEMENT
SOLUTION BRIEF DOSSIER MANAGEMENT BUSINESS CHALLENGES The end-to-end submission management process is very complex, supporting many cross-functional processes such as manufacturing, R&D document authoring
More informationG E N OM I C S S E RV I C ES
GENOMICS SERVICES ABOUT T H E N E W YOR K G E NOM E C E N T E R NYGC is an independent non-profit implementing advanced genomic research to improve diagnosis and treatment of serious diseases. Through
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationWhat s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials
Vol. 14, No. 10, October 2018 Happy Trials to You What s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials While multiple, concurrently accruing patient cohorts in first-in-human (FIH)
More informationRoadmap for Managing Multiple CRO Vendors
PharmaSUG 2017 - Paper PO27 Roadmap for Managing Multiple CRO Vendors Veena Nataraj, Shire, Lexington, MA Karin LaPann, Shire, Lexington, MA ABSTRACT When working with CROs, the relationship established
More informationEvolving Regulatory Guidance on Submission of Standardized Data. James R. Johnson, PhD RTP CDISC User Network
Evolving Regulatory Guidance on Submission of Standardized Data James R. Johnson, PhD RTP CDISC User Network 2014-06-11 Originally Presented at PhUSE Conference 2013 Brussels, Belgium (Paper Number: RG03)
More informationUsing SAS ETL Studio to Convert Clinical Trials Data to the CDISC SDTM Barry R. Cohen, Octagon Research Solutions, Wayne, PA
Paper FC04 Using SAS ETL Studio to Convert Clinical Trials Data to the CDISC SDTM Barry R. Cohen, Octagon Research Solutions, Wayne, PA ABSTRACT A new industry standard for clinical and preclinical trials
More informationRESPONSE TO RFP - Title Page
University of Pennsylvania RESPONSE TO RFP - Title Page Request for Proposal (RFP) Number: 002 Issue Date: July 16, 2008 Proposal Due Date: August 18 2008 Title of RFP: Central Laboratory for a Randomized
More informationNext Generation Oncology Sequencing in your Laboratory. Built by pioneers in cancer genomics and liquid biopsy approaches PROGENEUS
PROGENEUS Next Generation Oncology Sequencing in your Laboratory Built by pioneers in cancer genomics and liquid biopsy approaches For Research Use Only. Not for iagnostic Purposes. personalgenome.com/progeneus
More informationCDASH Clinical Data Acquisition Standards Harmonization
CDISC Italian User Group Meeting 16 November 2007 CDASH Clinical Data Acquisition Standards Harmonization 1 Outline Background Organization Goals Timelinesand Process Review of progress Results Future
More informationMarcia Brackman, Data Scientist Eli Lilly and Company
k Marcia Brackman, Data Scientist Eli Lilly and Company Adaptive Design: A clinical study design that uses accumulating data to decide how to modify aspects of the study as it continues, without undermining
More informationCDISC End-to-End UK User Group Meeting GSK, Stockley Park 24 th October 2007 Dave Iberson-Hurst CDISC VP Technical Strategy CDISC 2007 Dave Iberson-Hurst CDISC VP Technical Strategy Co-lead Technical Advisory
More informationData Standards for Population Pharmacokinetic Analysis (POPPK) and Non-Compartmental Analysis (NCA)
PharmaSUG 2018 - Paper AA-16 Data Standards for Population Pharmacokinetic Analysis (POPPK) and Non-Compartmental Analysis (NCA) Neelima Thanneer, Bristol-Myers Squibb Company, Princeton, NJ ABSTRACT Pharmacometrics
More informationDisclaimers The views expressed are those of the presenter and not necessarily of the FDA With the FDA, as with the stock market, past performance is
Managing Biometrics Tasks for an ectd Submission 1 Disclaimers The views expressed are those of the presenter and not necessarily of the FDA With the FDA, as with the stock market, past performance is
More informationAn Automated Pipeline for NGS Testing and Reporting in a Commercial Molecular Pathology Lab: The Genoptix Case
Cartagenia Bench Lab Case Study An Automated Pipeline for NGS Testing and Reporting in a Commercial Molecular Pathology Lab: The Genoptix Case At a Glance In this case study, you will learn: How the Molecular
More information2016 Technical Update. August 2016
2016 Technical Update August 2016 1 Foundational Standards Key Milestones CTR ODM XML Modernize CT Process CDISC Protocol Standards IntraChange Cross-team focus Survey CTR Content Governance: Consistent
More informationEnabling faster insights to improve clinical trial efficiency and quality
Enabling faster insights to improve clinical trial efficiency and quality Clarity, understanding and confidence Every clinical trial has moments when decisive action is needed to set the course for a
More informationDISCOVER DEFINE- XML PRACTICAL USES END-TO-END TODAY Mark Wheeldon CEO Formedix Bay Area User Group May 23, 2013
DISCOVER DEFINE- XML PRACTICAL USES END-TO-END TODAY Mark Wheeldon CEO Formedix Bay Area User Group May 23, 2013 AGENDA Introduction Your Clinical Trials Automated. Everywhere. Define Driven Dataset Libraries
More informationClinical Data Standards & Automation
Clinical Data Standards & Automation PhUSE 2007 Author: Giri Balasubramanian Company Name: Kinship Technologies Pvt. Ltd., Table of Contents EXECUTIVE SUMMARY... 3 1.0 INTRODUCTION... 4 2.0 WHY AUTOMATION?...
More informationDetermining How to Make Data Review More Efficient by Utilizing Visualization Tools. Susan Doleman, Replimune Inc.
Determining How to Make Data Review More Efficient by Utilizing Visualization Tools Susan Doleman, Replimune Inc. Study Data Review Why? In order to ensure Patient safety Looking for unknown risks Data
More informationLaboratory Management for Clinical and Research NGS Labs
Laboratory Management for Clinical and Research NGS Labs Introduction Few can argue that Next Generation Sequencing is having a major impact on genomics research. The progress in this field exceeds even
More informationAdvanced workflow of review/consultation
PMDA Update Yuki Ando, PhD Senior Scientist for Biostatistics Advanced Review with Electronic Data Promotion Group Pharmaceuticals and Medical Devices Agency CDISC 2016 1 Advanced workflow of review/consultation
More informationPeptide arrays for multiplex kinetic measurements Robust Instrumentation User friendly software
NUCLEAR RECEPTOR FUNCTION Peptide arrays for multiplex kinetic measurements Robust Instrumentation User friendly software Kinetic data at your fingertips! Novel platform for profiling nuclear receptor
More informationSTRATEGIC RESOURCING. inventivhealthclinical.com
STRATEGIC RESOURCING inventivhealthclinical.com 1 Table of Contents OVERVIEW 02 STAFFING 03 MOVING UP THE VALUE CHAIN 04 FUNCTIONAL EXPERTISE Biostatistics and Statistical Programming 05 Clinical Monitoring
More informationPAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
More informationCDISC Data Standards Validation
CDISC Data Standards Validation How can it be done? Peter Van Reusel Business Unit Director Business & Decision Life Sciences Tel +32 2 774 11 00 Fax +32 2 774 11 99 Mobile +32 476 54 59 17 peter.vanreusel@businessdecision.com
More informationInspection-Ready IRT. Valarie Higgins President & Managing Director Almac Clinical Technologies.
Inspection-Ready IRT Valarie Higgins President & Managing Director Almac Clinical Technologies www.almacgroup.com 2 Biologics License Application and the IRT Provider IRT 3 Agenda Why is IRT Becoming an
More informationImplementation of ADaM Basic Data Structure on Genetic Variation Data for Pharmacogenomics Studies
PharmaSUG 2018 - Paper DS-22 Implementation of ADaM Basic Data Structure on Genetic Variation Data for Pharmacogenomics Studies Linghui Zhang, Merck & Co., Inc. ABSTRACT Genetic variations have essential
More informationExploration des données d essais cliniques en utilisant le standard CDISC
Exploration des données d essais cliniques en utilisant le standard CDISC Florence Kussener French System Engineer Florence.Kussener@jmp.com SAS Institute AGENDA Outcomes of using CDISC standards Case
More information! Background. ! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs) ! Consequences in General
! Background! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs)! 5 Approaches (Table 3) for:! Microdose trials (7.1)! Single-Dose (SD) Trials at Sub-therapeutic Doses or Into the
More informationFDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer
FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer Yongjie Zhou, M.D., Ph.D. FDA/CBER/OCTGT/DCEPT Yongjie.zhou@fda.hhs.gov isbtc Global Regulatory Summit October 29, 2008
More informationThe In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
More informationStart With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development. Paul Docherty PhD Relationship Management
Start With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development Paul Docherty PhD Relationship Management Disclaimer This presentation contains my personal views and research
More information